Asciminib Pediatric formulation group

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

NVSPhase 2$274.7B

Asciminib Pediatric formulation group Phase 2 Results Expected

Asciminib Pediatric formulation group• Myeloid Leukemia, Philadelphia Positive44

Jun 30Estimated

00%

Competitive Landscape

0 competitors in Myeloid Leukemia, Philadelphia Positive

Drug Information

Target Indication

Myeloid Leukemia, Philadelphia Positive

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Influenza

Heart Transplantation

Non-alcoholic Fatty Liver Disease (NAFLD)

Meningococcal Meningitis

Axial Spondyloarthritis